

2015 BMT Pharmacists Conference

Held in Conjunction with the
2015 BMT Tandem Meetings
February 11 - February 15, 2015
Manchester Grand Hyatt
San Diego, California

For more information about the 2015 BMT Pharmacist Conference, visit www.cibmtr.org or www.asbmt.org. No brochures will be mailed this year.

Pharmacist Continuing Education Information



Syntaxx Communications, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Syntaxx Communications has assigned 12.00 contact hours (1.200 CEUs) of continuing pharmacy education credit for this knowledge- and application-based activity. This 2-day conference will incorporate 14 individual activity sessions that combined will fulfill the 12.0 hours of CE. The target audience for this accredited activity is pharmacists.

To receive continuing pharmacy education credit for the conference, participants must attend the sessions in their entirety and complete the associated program evaluation forms. Additionally, all US-based pharmacists must supply their National Association of Boards of Pharmacy (NABP) electronic Profile Identification (ePID) number and their birth month and day (MM/DD). No credit can or will be issued without this information. To acquire an NABP ePID, go to <http://www.nabp.net> and click on CPE Monitor.

Faculty and Agenda

See below for full list of faculty and the 2-day agenda

Published

February 12, 2015 – February 11, 2018

Universal Activity Numbers

0299-9999-15-006-LO1-P – 0299-9999-15-019-LO1-P; this is a 2-day conference with multiple activities. There will be 14 individual sessions identified by 14 distinct UAN numbers.

Overall Conference Educational Objectives

After attending the 2015 BMT Pharmacists Conference, participants should be able to:

1. Discuss the management of patients undergoing hematopoietic cell transplantation (HCT).
2. Analyze the results of recent clinical trials in the field of HCT.
3. Describe the principles of stem cell mobilization guidelines in HCT practice.
4. Summarize recent literature regarding new medications used in HCT patients.
5. Apply recent advances in treating infectious diseases to HCT recipients.
6. Describe immune reconstitution mechanisms and select immunization strategies for HCT recipients.
7. Outline the current issues regarding HCT in patients with Fanconi anemia.

8. Select preparative regimen dose adjustments for obese HCT patients or those with renal or hepatic impairment.
9. Discuss treatment options for ocular chronic graft-versus-host disease (GVHD).
10. Discuss management of cardiovascular complications in HCT patients.
11. Interpret current investigative options for the management of GVHD.
12. Compare and contrast busulfan and cyclophosphamide conditioning with busulfan and fludarabine conditioning in myeloid malignancies.

Program Evaluation Forms

The program evaluation forms may be accessed and completed online. These forms can be accessed during the conference via laptops available at various kiosks or using personal computers via a link provided on the CIBMTR and/or ASBMT Web sites (www.cibmtr.org or www.asbmt.org). To access the Session Evaluation links, you will need your registration **badge number**; your badge number is provided on your name badge. Once logged on, choose the type of credit you wish to receive (ACPE), select the program you wish to evaluate, and complete the forms accordingly. When you are done, click **Submit**. The program will be redirected to the main menu, where you may select additional programs for evaluation. All participants completing program evaluation forms should be able to print a statement of continuing education.

For problems or issues related to continuing pharmacy education, please contact Terri at Syntaxx Communications:

E-mail: tdavidson@syntaxxcomm.com

Phone: 678.584.9503

Mail: 305 W Country Dr, Johns Creek, GA 30097

Fees

No additional fee for the 2-day (February 13, 2015 – February 14, 2015) BMT Pharmacists Conference will be charged to attendees requesting CE. Registration for the BMT Tandem Meetings (February 11, 2015 – February 15, 2015) covers attendance and CE for any/all CE activities. (Advance Registration- \$399; Standard Registration - \$545; Late Registration - \$645)

Required Computer Hardware/Software

Educational materials and handouts will be posted on the ASBMT Web site and available for registrants to print before the activities commence during this 2-day conference. Registrants are encouraged to print the materials before arriving at the conference. Printers will not be available onsite for conference attendee use. A business center will be available to those willing to pay for copies.

Registrants will need an Internet connection in order to use the mobile application or access the Web site using electronic devices, such as a PC, Mac, tablet, or smart phone. Please note that PC and Apple computers do not support the Bravura Technologies Mobile Application that will be used for the ARS portion of each activity. The application to search and download for an IOS/Android tablet/mobile phone is BMTTANDEM (Bravura Technologies).

Financial Support

Otsuka
Amgen
Jazz
Spectrum
Onyx
Pharmacyclics

Financial Disclosures

Jamie Shapiro, PharmD - Onyx: Advisory Board
Amin Alousi, MD - Therakos: Honoraria, Research Funding; Alexion: Research Funding, Advisory Board; Terumo BCT: Consultancy
Patrick Kiel, PharmD - Celgene, Millennium, Takeda: Honoraria; Eisai: Advisory Board
Susanne Liewer, PharmD - Amgen: Honoraria; Bristol-Meyers-Squibb: Honoraria; Seattle Genetics: Honoraria
Ashley Morris Engemann, PharmD - Astellas: Advisory Board
Daniel Lenihan, MD - Roche: Consultancy; Onyx: Consultancy; Incyte: Consultancy; Acorda Inc. and Millennium, Inc: Research Support
Pierre Noel, MD - Novartis: spouse is director; Blood System: Board of Directors
Steve Stricker, PharmD - Takeda Oncology; consulting fees, salary
(No other faculty or program planning committee member has known relevant conflicts of interest to disclose)

Agenda: BMT Pharmacists Conference at the 2015 BMT Tandem Meetings

Thursday, February 12, 2015

6:00 pm to 7:30 pm **Pharmacy Reception/Registration Opens**

Friday, February 13, 2015

7:45 am to 8:30 am Registration Opens

8:30 am to 8:45 am **Welcome and Overview**
Amber Lawson, PharmD
Chair, Program Planning Committee; Clinical Coordinator, Hematology/Oncology Pharmacy Services at UK HealthCare

8:45 am to 9:15 am **ASBMT Pharmacy SIG Update**
Jamie Shapiro, PharmD
Chair, ASBMT Pharmacy SIG Steering Committee; Clinical Coordinator, Blood and Stem Cell Transplantation; H. Lee Moffitt Cancer Center and Research Institute

9:15 am to 10:15 am **American Society of Hematology (ASH) Meeting Updates**
Steve Stricker, PharmD, MS
Associate Director, US Medical Affairs; Medical Science Liaison: Takeda Oncology

10:15 am	to 10:30 am	Break
10:30 am	to 11:15 am	<p>New Drug Update Alex Ganetsky, PharmD Hematology/Oncology Clinical Pharmacy Specialist; Hospital of the University of Pennsylvania</p>
11:15 am	to 12:00 pm	<p>Cardiovascular Considerations in HCT Daniel Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Cardiology Clinical Research Cardio-Oncology Program; Vanderbilt University Medical Center</p>
12:00 pm	to 1:30 pm	Lunch Break
1:45 pm	to 3:00 pm	<p>Best Abstracts</p> <p>Abstract 5246: Comparison of Outcomes of Two Preparative Regimens for Lymphoma Patients Who Are Receiving Autologous Hematopoietic Stem Cell Transplantations Presenter: LeAnne Kennedy, PharmD Wake Forest University Baptist Medical Center</p> <p>Abstract 5410: Dose-Escalated G-CSF Does Not Improve Resolution of Neutropenia Compared to Standard-Dose G-CSF Following Autologous Stem Cell Transplantation Presenter: Steven Trifilio, BSPHarm Northwestern Memorial Hospital</p> <p>Abstract 5671: Folinic Acid Rescue after Methotrexate Graft Versus Host Disease Prophylaxis to Reduce Mucositis and Improve the Probability of Day +11 Methotrexate Administration – Role of the Hematopoietic Cell Transplant Pharmacist in Development of Program Guidelines Presenter: Jeffrey Betcher, BSPHarm Mayo Clinic Arizona</p> <p>Abstract 5968: Evaluation of the Impact of Anti-Thymocyte Globulin (ATG) on Post-Hematopoietic Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Presenter: Katie Kaminski, PharmD University of North Carolina Hospitals and Clinics</p>
3:00 pm	to 3:30 pm	<p>How I Treat Ocular Graft-Versus-Host Disease: Contact Bandage Lens Therapy Tueng Shen, MD, PhD Professor, Ophthalmology; Adjunct, Bioengineering and Global Health; University of Washington</p>
3:30 pm	to 3:45 pm	Break
3:45 pm	to 4:45 pm	<p>Infectious Diseases Update Jill Leslie, PharmD Clinical Specialist: BMT/Hematology Services; Indiana Blood and Marrow Transplant; St. Francis Hospitals and Health Centers</p>

Saturday, February 14, 2015

8:25 am	to 8:30 am	Overview Kelly Hawks, PharmD Chair-Elect, Program Planning Committee; Clinical Pharmacy Specialist, Stem Cell Transplant; Virginia Commonwealth University Medical Center
8:30 am	to 9:00 am	Immune Reconstitution in HCT Patrick Kiel, PharmD Clinical Pharmacy Specialist, Hematology/Stem Cell Transplant; Indiana University Health, IU Simon Cancer Center
9:00 am	to 10:00 am	Best Practices: Immunization Strategies and Monitoring Tracey Walsh-Chocolaad, PharmD Hematology/Oncology Pharmacist; The Nebraska Medical Center Maurice Alexander, PharmD Clinical Pharmacy Specialist, Hematology/Oncology/HSCT; University of North Carolina Hospitals and Clinics Cathryn Jennissen, PharmD Pediatric Clinical Pharmacist, Hematology/Oncology/Hematopoietic Stem Cell Transplant; University of Minnesota Children's Hospital
10:00 am	to 10:05 am	Best Pharmacy Abstract Award Announcement
10:05 am	to 10:15 am	Break
10:15 am	to 11:00 am	Mobilization Guideline Update: Strategies for Autologous and Allogeneic Hematopoietic Cell Transplantation Susanne Liewer, PharmD Clinical Pharmacy Specialist, Blood and Marrow Transplant; The Nebraska Medical Center
11:00 am	to 12:00 pm	Preparative Regimens: Dosing Considerations in Special Populations Megan Bodge, PharmD - BMT Clinical Pharmacy Specialist; VA Tennessee Valley Healthcare System Joe Bubalo, PharmD, MBA - Assistant Professor of Medicine-Oncology Pharmacy Clinical Specialist; OHSU Hospitals and Clinics
12:00 pm	to 1:30 pm	Lunch Break
1:30 pm	1:45 pm	ASBMT Pharmacy SIG New Practitioner Award
1:45 pm	to 2:45 pm	Graft-versus-Host Disease: Looking Ahead Amin Alousi, MD Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine; The University of Texas M. D. Anderson Cancer Center
2:45 pm	to 3:45 pm	HCT in Fanconi Anemia Melisa Stricherz, PharmD

Clinical Pediatric Pharmacist-Hematopoietic Cell
Transplant/Hematology/Oncology; University of Minnesota Children's Hospital

3:45 pm to 4:00 pm Break

Preparative Regimens Debate: BuCy versus BuFlu for Myeloid Malignancies

4:00 pm to 5:00 pm Don Hutcherson, BSPHarm - Clinical Pharmacy Specialist - Bone Marrow Transplant; Emory Healthcare/Winship Cancer Institute

Ashley Morris Engemann, PharmD - Clinical Associate in the Department of Medicine; Division of Hematologic Malignancies and Cellular Therapy Duke University Medical Center

Wrap-Up/Adjourn

5:00 pm to 5:15 pm Kelly Hawks, PharmD
Chair-Elect, Program Planning Committee; Clinical Pharmacy Specialist, Stem Cell Transplant; Virginia Commonwealth University Medical Center